Large Inflow of Money Detected in Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals Ltd. (FOMX) stock had a bullish inflow of $0.91 million worth of trades on uptick and an outflow of $0.05 million in downticks on Monday. The total uptick to downtick ratio stood at 17.16. The net money flow into the stock was $0.86 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.85 million. $0.85 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Foamix Pharmaceuticals Ltd. (FOMX) stock traded down $0.04 , and reached $8.51, a drop of -0.47% over the previous day. On a weekly basis, the stock is 3.78%, over the previous weeks close.


Shares of Foamix Pharmaceuticals Ltd. rose by 9.76% in the last five trading days and 26.06% for the last 4 weeks. Foamix Pharmaceuticals Ltd. is up 26.61% in the last 3-month period. Year-to-Date the stock performance stands at 6.78%.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.62 and $8.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.76. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.66, notching a gain of 1.29% for the day. The total traded volume was 262,110 . The stock had closed at $8.55 on the previous day.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its minocycline foam for the treatment of acne, impetigo and other skin conditions. The Companys product candidates include, FMX101 for moderate-to-severe acne, is a topical foam formulation of the antibiotic minocycline; FMX102 for impetigo, FMX103 for rosacea and FDX104 for chemotherapy-induced rash. The Company has conducted only one Phase II clinical trial of each of FMX101 and FMX102 which met the respective primary efficacy and secondary endpoints. The Company developed FMX101, FMX102, FMX103 and FDX104 using its technology, which includes its foam-based platforms. This technology enables it to formulate and stabilize a variety of drugs and deliver them directly to target site. The Company has entered into development and license agreements relating to its technology with Bayer HealthCare AG (Intendis), Merz Pharmaceuticals, LLC and Actavis plc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.